Last reviewed · How we verify
PT010
At a glance
| Generic name | PT010 |
|---|---|
| Also known as | PT010; Budesonide, Glycopyrrolate, and Formoterol Fumarate Inhalation Aerosol |
| Sponsor | Pearl Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS) (PHASE3)
- Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS) (PHASE3)
- Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PHASE3)
- A Scintigraphy Study of PT010 in COPD Patients (PHASE1)
- Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos) (PHASE3)
- A Study to Assess the PK and Safety of PT010 in Subjects With COPD Following Single and Repeat Dose (PHASE1)
- Pharmacokinetics and Safety Study of PT010 and PT003 in Healthy Chinese Adult Subjects (PHASE1)
- A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PT010 CI brief — competitive landscape report
- PT010 updates RSS · CI watch RSS
- Pearl Therapeutics, Inc. portfolio CI